
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV's positive outlook is bolstered by a significant increase in peak revenue estimates for its gene therapy AMT-130 for Huntington's disease, projected to reach approximately $3 billion. The company has demonstrated a favorable safety profile for AMT-130, alongside sustained efficacy and biomarker improvements, which solidify its potential as the first disease-modifying treatment for Huntington's disease. Furthermore, the commercial infrastructure appears well-prepared to facilitate a robust launch in 2026, indicating strong future market entry capabilities.
Bears say
uniQure NV's financial outlook appears negative due to the company’s reliance on a high-risk gene therapy pipeline, especially for complex diseases such as Huntington's disease and cardiovascular conditions. Despite presenting statistically significant results in clinical trials, such as a 75% slowing of decline in neuromarkers, the long-term commercial viability and reimbursement potential of these therapies remain uncertain. Moreover, the collaboration with Bristol Myers Squibb may not sufficiently mitigate financial risks associated with research and development expenditures inherent in the gene therapy sector.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares